BTK inhibitor ibrutinib is cytotoxic to myeloma and potently enhances bortezomib and lenalidomide activities through NF-κB

S Rushworth, KM Bowles, LN Barrera Briceno, MY Murray, L Zaitseva, DJ Macewan

Research output: Contribution to journalArticle

81 Citations (Scopus)
Original languageEnglish
Pages (from-to)106-112
Number of pages7
JournalCellular Signalling
Volume25
Issue number1
DOIs
Publication statusPublished - 2013

Cite this